Condition: Osteosarcoma Recurrent · Osteosarcoma in Children · Relapsed Osteosarcoma · Sponsor: Emory University
The goal of this clinical trial is to define the maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D) of Tegavivint in combination with Gemcitabine in patients with relapsed or refractory osteosarcoma (OS). The study will also investigate the toxicities of Tegavivint in combination with gemcitabine in patients with relapsed or refractory OS.
This description comes directly from the study's public registry record.
Kate Glasscox, BSN, RN · 404-785-0002 · aflacdevtreferral@choa.org
Melissa Schink · DevTcoordinators@choa.org
Always discuss trial participation with your own doctor first.
| Arthur M. Blank Children's Healthcare of Atlanta | Atlanta, Georgia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07144254